Version June 2024
| Vaccine | Diphtheria toxoid (Lf units) | Tetanus toxoid (Lf units) | Pertussis antigens | Approved doses and age groups |
| Vaccines for children 6 weeks through 6 years | ||||
| DT* | 6.7 | 5 | None | All 5 doses if there is a contraindication or precaution to pertussis vaccine (6 weeks through 6 years) |
| DTaP | ||||
| Daptacel | 15 | 5 | PT (10 mcg) FHA (5 mcg) PERT (3 mcg) FIM (5 mcg) | All 5 doses (6 weeks through 6 years) |
| Infanrix | 25 | 10 | PT (25 mcg) FHA (25 mcg) PERT (8 mcg) | All 5 doses (6 weeks through 6 years) |
| DTaP combination vaccines | ||||
| Kinrix (DTaP + IPV) | 25 | 10 | PT (25 mcg) FHA (25 mcg) PERT (8 mcg) | Fifth dose of DTaP, fourth dose of IPV (4 through 6 years) in children who have received 4 doses of Infanrix and/or Pediarix |
| Pediarix (DTaP + IPV + HBV) | 25 | 10 | PT (25 mcg) FHA (25 mcg) PERT (8 mcg) | All 5 doses (6 weeks through 6 years) |
| Pentacel (DTaP + IPV + Hib) | 15 | 5 | PT (20 mcg) FHA (20 mcg) PERT (3 mcg) FIM (5 mcg) | Four-dose series (6 weeks through 4 years) |
| Vaxelis (DTaP + IPV + Hib + HBV) | 15 | 5 | PT (20 mcg) FHA (20 mcg) PERT (3 mcg) FIM (5 mcg) | Three-dose series (6 weeks through 4 years) |
| Quadracel (DTaP + IPV) | 15 | 5 | PT (20 mcg) FHA (20 mcg) PERT (3 mcg) FIM (5 mcg) | Fifth dose of DTaP, fourth dose of IPV (4 through 6 years) in children who have received 4 doses of Daptacel or Pentacel |
| Vaccines for children ≥7 years, adolescents, and adults | ||||
| Td | 2 | 2 to 5 | None | Booster dose (≥7 years) |
| Tdap | ||||
| Adacel | 2 | 5 | PT (2.5 mcg) FHA (5 mcg) PERT (3 mcg) FIM (5 mcg) | Booster dose (10 through 64 years)¶ |
| Boostrix | 2.5 | 5 | PT (8 mcg) FHA (8 mcg) PERT (2.5 mcg) | ≥10 years¶ |
Lf: limit of flocculation; DT: diphtheria and tetanus toxoids; DTaP: diphtheria toxoid, tetanus toxoid, acellular pertussis vaccine; PT: inactivated pertussis toxin (toxoid); FHA: filamentous hemagglutinin; PERT: pertactin (an outer membrane 69-kd protein); FIM: fimbrial proteins types 2 and 3; IPV: inactivated polio vaccine; HBV: hepatitis B vaccine; Hib: Haemophilus influenzae type b vaccine; Td: tetanus, reduced diphtheria; Tdap: tetanus, reduced diphtheria, acellular pertussis.
* As of early 2023, the sole manufacturer discontinued production and distribution of the DT vaccine.
¶ The Advisory Committee on Immunization Practices (ACIP) recommends off-label use of Tdap vaccine for catch-up immunization of children age 7 through 9 years and permits off-label use of Tdap vaccine in a number of other clinical scenarios (eg, wound management in children age 7 through 9 years).[1,3] Refer to UpToDate content on diphtheria, tetanus, and pertussis immunization for details.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
